Avelumab Produces Durable Responses in Metastatic Merkel Cell Carcinoma
In this video we discuss promising results of the anti–PD-L1 agent avelumab in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy.
The phase II JAVELIN Merkel 200 trial found that the anti–PD-L1 agent avelumab produced durable responses in patients with metastatic Merkel cell carcinoma who had previously been treated with chemotherapy, according to data presented at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held earlier this month in Chicago (abstract 9508).
In this video, Howard L. Kaufman, MD, of the Rutgers Cancer Institute of New Jersey, discusses these results.
Oncology On-The-Go Podcast: ASCO 2023 Recap
June 19th 2023Experts from University of California, Los Angeles Health and Mayo Clinic discuss key data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in the gynecologic and gastrointestinal cancer spaces and how they may impact patient care.
